Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis
Year: 2012
Type: article
Abstract: Glioblastoma, the most common primary malignant cancer of the brain, is characterized by rapid tumor growth and infiltration of tumor cells throughout the brain. These traits cause glioblastomas to be highly resistant to current therapies with a resultant poor prognosis. Although aberrant oncogenic signaling driven by signature genetic alterations, such as EGF receptor (EGFR) gene amplification and mutation, plays a major role in glioblastoma pathogenesis, the responsible downstream mechanisms remain less clear. Here, we report that EGFRvIII (also known as ΔEGFR and de2-7EGFR), a constitutively active EGFR mutant that is frequently co-overexpressed with EGFR in human glioblastoma, promotes tumorigenesis through Src family kinase (SFK)-dependent phosphorylation of Dock180, a guanine nucleotide exchange factor for Rac1. EGFRvIII induces phosphorylation of Dock180 at tyrosine residue 722 (Dock180(Y722)) and stimulates Rac1-signaling, glioblastoma cell survival and migration. Consistent with this being causal, siRNA knockdown of Dock180 or expression of a Dock180(Y722F) mutant inhibits each of these EGFRvIII-stimulated activities. The SFKs, Src, Fyn, and Lyn, induce phosphorylation of Dock180(Y722) and inhibition of these SFKs by pharmacological inhibitors or shRNA depletion markedly attenuates EGFRvIII-induced phosphorylation of Dock180(Y722), Rac1 activity, and glioblastoma cell migration. Finally, phosphorylated Dock180(Y722) is coexpressed with EGFRvIII and phosphorylated Src(Y418) in clinical specimens, and such coexpression correlates with an extremely poor survival in glioblastoma patients. These results suggest that targeting the SFK-p-Dock180(Y722)-Rac1 signaling pathway may offer a novel therapeutic strategy for glioblastomas with EGFRvIII overexpression.
Institutions: UPMC Hillman Cancer Center, University of Pittsburgh, Cell Signaling Technology (United States), Monash Institute of Medical Research, Georgetown University, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, Saitama Medical University, Mayo Clinic, University of California San Diego, University College London, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, State Key Laboratory of Experimental Hematology
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
Funders: James S. McDonnell Foundation, Pennsylvania Department of Health, University of Pittsburgh, National Institutes of Health, Cancer Institute, University of Pittsburgh, National Key Research and Development Program of China, National Heart, Lung, and Blood Institute, National Cancer Institute, National Center for Research Resources, National Center for Advancing Translational Sciences
Awards: Molecular Mechanisms of Blockage of ErbB receptors, University of Pittsburgh Clinical and Translational Science Institute, University of Pittsburgh Clinical and Translational Science Institute, ELMO1, Dock180 and Glioma Invasion, Stem Cell Efficiency Regulated by CDK Inhibitors, G6966134840, Signaling Interactions in Cell Survival and Invasion, Mayo SPORE in Brain Cancer, G7950859287, Genetics and Biology of Malignant Glioma, Cancer Center Support Grant, G948547148
OpenAlex ID: W2053948677
